Neuroprotective effects of glucotropaeolin as the major glucosinolate of cress seed on cuprizone-induced mouse model of multiple sclerosis Authors: Masoumeh Bathaee, Mohammad Seyedabadi, Mohammad Shokati Sayyad, Somayeh Sheidaei, Somayeh Shahani Published: 2026 ABSTRACT Multiple sclerosis (MS) is a neurodegenerative disease characterized by inflammation and myelin damage. Glucosinolates, present in Lepidium sativum L. (garden cress) seeds (LSS), exhibit anti-inflammatory properties. This study evaluates the anti-inflammatory and neuroprotective effects of glucosinolate-rich and volatile fractions from LSS in a MS mouse model. C57BL/6 male mice were divided into seven groups: Normal, cuprizone (0.4% diet for 8 weeks), positive control (dimethyl fumarate), and groups receiving LSS glucosinolate (1, 10 mg/kg, oral) and volatile fractions (1, 10 mg/kg, subcutaneous) daily for 21 days. Behavioral, histopathological and gene expression analysis were performed. LSS glucosinolate fraction contained glucotropaeolin as the major constituent, and the volatile fraction confirmed presence of benzyl isothiocyanate. Behavioral tests demonstrated symptom improvement, and histopathological analysis revealed enhanced remyelination. Additionally, the expression of myelination-related gene, Olig2, showed significant changes. LSS fractions promote neuroprotection in MS via remyelination, with minimal impact on Nrf2 and Nf-κB pathways. Abbreviations BITC Central nervous system Cuprizone Gas chromatography-mass spectrophotometry Glucosinolates Dimethylfomarate Hematoxylin-eosin Isothiocyanates Luxol fast blue Lepidium sativum seed Multiple sclerosis Nuclear factor erythroid 2-related factor 2 Nuclear factor kappa-light-chain-enhancer of activated B cells Subcutaneous Introduction “Garden cress” or Lepidium sativum L., is an annual herb from Brassicaceae family, which is widely used as a food source by Iranian people. It is native to west Asia and also cultivated in temperate areas globally [1]. Various parts of the plant exhibit different biological activities, among which the most important are hepato-protective, wound healing, antioxidant, anticancer, and anti-inflammatory [[2], [3], [4], [5]]. The plant contains a rich variety of secondary metabolites, such as sulfur-containing compounds, particularly glucosinolates (GLSs), alkaloids, saponins, phenolic and flavonoid compounds, terpenes and essential fatty acids [3,6,7]. Glucotropaeolin and gluconasturtiin have been reported as the main GLSs from the seeds of L. sativum [4,8]. These compounds are enzymatically hydrolyzed into isothiocyanates, thiocyanates and nitriles [9,10]. Isothiocyanates are key contributors to the biological effects of Brassicaceae plants, including garden cress [11,12]. Multiple Sclerosis (MS) is a chronic, progressive, autoimmune demyelinating disease of the central nervous system that affects sensory and motor function. This disease is predominantly observed in adults aged between 20 and 40 years and is more frequent in females than in males [13,14]. According to studies, the disease prevalence is rapidly increasing in Iran [15,16]. The pathology of MS is characterized by inflammation, demyelination, reactive gliosis and neuroaxonal injury. Relapses typically coincide with the presence of inflammatory demyelinating lesions within the central nervous system (CNS) that are detectable by magnetic resonance imaging (MRI). These lesions are hallmarks of the disorder, and result from the invasion of the brain and spinal cord by peripheral immune cells, leading to the destruction of myelin sheaths [[17], [18], [19]]. Oxidative stress and inflammation have been established as the predominant etiologies for this condition, according to studies. Inflammation can trigger the activation of microglial cells and astrocytes, ultimately leading to the increased secretion of proinflammatory cytokines, such as TNF-α, IL-1β, and IFN-γ. This process initiates the onset of demyelination, Oligodendrocyte damage, and axonal injury [[20], [21], [22]]. Nrf2 is considered to be one of the most significant factors in the oxidative stress defense mechanism, as it produces proteins that possess the capability to resist myelin sheath damage and neuronal degeneration [23]. Considering this point, bioactive compounds with antioxidant and anti-inflammatory properties could also be applied in the therapeutic management of this disease. Although the exact etiology of MS remains elusive, evidence points to immune activation involving microglia and macrophages, which produce pro-inflammatory cytokines and chemokines ‒ such as IL-16 and IL-17‒ that drive MS-associated inflammation [24,25]. Considering that the mechanisms of multiple sclerosis do not fully explain the damage caused by this disease, animal models now play a role in experiments investigating the pathophysiology of MS. In recent years, the utilization of natural compounds in managing diseases such as MS has garnered substantial attention. Secondary metabolites, including flavonoids, alpha-lipoic acid, anthocyanins, and essential oils, have demonstrated therapeutic potential in both relapsing-remitting and progressive forms of MS [[26], [27], [28]]. Several studies have documented the beneficial impact of glucosinolates on the anti-inflammatory activities [29,30]. Their hydrolysis products, isothiocyanates (ITCs), play a significant role in this process and in oxidative stress by regulating the Nuclear factor erythroid 2-related factor 2 (Nrf2) and Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways [31]. Several studies support the neuroprotective activity of isothiocyanates such as sulforaphane in neurodegenerative diseases like MS [[32], [33], [34], [35], [36]]. Various types of animal models are used to investigate the inflammatory demyelination and neurodegenerative pathways involved in MS, one of the most common being the toxin-induced model using cuprizone (CPZ). In this model, mice are fed a diet containing CPZ, which leads to apoptosis of oligodendrocytes and primary demyelination [37,38]. To our knowledge, no previous reports have demonstrated the potential efficacy of L. sativum seed( LSS) and its fractions in MS. Therefore, the present study aimed to investigate the effects of LSS glucosinolates fraction (GF) orally and volatile fraction (VF) subcutaneously (Sc) on a cuprizone-induced MS animal model, compared to the conventional standard drug; dimethyl fumarate (DMF). Glucosinolates undergo hydrolysis in the body following oral administration, converting into isothiocyanates, which are their active forms. Therefore, this study compared the efficacy of orally administrated glucosinolates with that of isothiocyanates directly administrated via injection. This study evaluates histopathological and behavioral changes, as well as gene expression analysis conducted by qRT-PCR to explore possible neuroprotective effects. Material and methods Chemicals and reagents Cuprizone [bis(cyclohexanone) oxaldihydrazone] was purchased from Sigma-Aldrich Chemical Co. (St. Louis, USA). Imidazole anhydrous, lead (II) acetate trihydrate, HPLC-grade acetonitrile, HPLC-grade methanol and gallic acid were obtained from Merck Co. (Darmstadt, Germany). Formic acid, sodium acetate, Helix pomatia type H-1 sulphatase, DEAE-Sephadex A25, potassium ferricyanide and Barium acetate were purchased from Sigma-Aldrich Chemical Co. (St. Louis, USA). Dimethyl fumarate was purchased from Abidi Co. (Iran). RNA isolation and reverse transcriptase kits were obtained from Zist Virayesh Co. (Iran). Plant material The seeds of L. sativum were purchased from “Pakan Bazr” Co. (Isfahan, Iran) in February 2024 and was authenticated by a pharmacognosist, and the voucher specimen (MAZUMS-A1025) was deposited at the Herbarium of Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran. The seeds were manually cleaned and uniformed, then stored at 4°C. Sample preparation and extraction of glucosinolate fraction (GF) A total of 2.5 g of plant seeds were preheated at 75°C for 5 min in a glass beaker, followed by rapid grinding using a mortar and pestle to obtain a fine powder. Crude glucosinolates were extracted using 25 mL of 70% (v/v) boiling methanol in a water bath maintained at 75°C for 15 min to deactivate endogenous myrosinase activity. The mixture was subjected to ultrasonication for 15 min, then centrifuged at 8000 rpm for 10 min. The supernatant was collected, and the residue was re-extracted twice under identical conditions. All supernatants were combined to yield the crude extract [39,40]. Column preparation and sulfatase treatment The extract was applied to a column (20 × 3.5 cm, up to 7 cm) packed with DEAE Sephadex A-25, which was pre-soaked in 2 M acetic acid and subsequently activated with 25 mL of imidazole formate solution (20 g imidazole dissolved in 50 mL of 30% aqueous formic acid). Non-bound plant material was removed with two washes of 25 mL each, using 70% methanol and 2 M sodium acetate (pH 5.5), respectively. Sodium acetate buffer was utilized to adjust the pH of the resin for subsequent desulfation [41]. A total of 1.875 mL of purified sulfatase (type H1, 10 KU, Sigma, S9626) was added to the column, which was then incubated overnight (16–18 h) at room temperature. Post-incubation, desulfo-glucosinolate were eluted with 8 washes of 25 mL each of deionized water. Fractions exhibiting similar chromatographic profiles were subsequently mixed and was thoroughly dried using a rotary evaporator followed by freeze-drying, and subsequently stored at refrigerated conditions until further analyses. Fraction was monitored by Thin-Layer Chromatography (TLC) on silica gel 60 F_254 plates. The spots were visualized under UV light at 254 and 365 nm, as well as by staining with iodine vapor and vanillin-sulfuric acid reagent. For the qualitative characterization of the compounds present in the fraction collected from the chromatographic column, an integrated analytical approach was employed, combining high-performance liquid chromatography (HPLC), infrared spectroscopy (IR), mass spectrometry (MS), and nuclear magnetic resonance (NMR) spectroscopy. HPLC analysis of the glucosinolate fraction Analytical HPLC was employed to evaluate the composition of the fraction. The analysis was performed using a Knauer HPLC system (Smartline Manager 5,000, Knauer, Germany). Chromatographic separation was performed on a C18 column (250 mm × 4.6 mm i. d., 5 μm particle size) at room temperature with UV detector. A volume of 20 μL of sample was filtered through a 0.22 μm and injected each time. The chromatographic separation was performed at a flow rate of 1 mL/min, employing a gradient elution composed of water (solvent A) and acetonitrile (solvent B). The elution program was as follows: an initial hold at 1% B for 1 min; a linear gradient increasing from 1% to 22% B over 21 min; and a linear decrease back to 1% B over the subsequent 18 min. Detection of desulfo-GLs was carried out by monitoring the absorbance at 229 nm. The data acquisition and integration were performed with EZchrom Elite 3.2.0 software [42]. Identification of the isolated compound Identification of the compound was achieved through the application of various analytical techniques, including NMR spectroscopy and mass spectrometry .1H and 13C-NMR spectra were recorded on a Bruker Ultrashield 300 MHz-Advance III spectrometer. The sample was dissolved in deuterated water (D2O) and chemical shifts were reported in ppm relative to the residual solvent peak [43]. The sample was also directly introduced into the mass spectrometer (MS) of an Agilent 5975 Gas chromatography-mass spectrometry (GC-MS) system, bypassing the gas chromatographic column. The analysis was conducted using electron ionization mass spectrometry (EI-MS) at an ionization energy of 70 eV. Mass spectra were acquired over a range of 40-500 (m/z) in scan mode. Preparation of volatile fraction (VF) A quantity of 100 g of dried LSS was ground using electric grinder, homogenized with deionized water and subjected to hydrodistillation using a Clevenger-type adapted to a 3000 mL round-bottom flask Apparatus for approximately 4 h [44,45]. The collected fraction was initially dried over anhydrous sodium sulfate and subsequently stored in a refrigerator at 4 °C prior to GC-MS analysis. GC-MS analysis of the volatile fraction Analyses were performed using an Agilent 5975 MSD mass spectrometer coupled to an Agilent 7890 GC system equipped with a HP-5MS capillary column (30 m length × 0.25 mm i.d., 0.25 μm). The oven temperature program was initiated at 35 °C and held for 5 min, followed by a temperature ramp of 5 °C/min to 200 °C. Subsequently, the temperature was increased to 280 °C at a rate of 10 °C/min and maintained for 9 min. The total runtime was 60 min. The sample injection temperature was set at 260 °C with the volume of 1 μL. Helium was employed as the carrier gas at a constant flow rate of 1 mL/min. The injection was performed in split mode with a split ratio of 1:1. Electron ionization (EI) was used at an ionization energy of 70 eV. Retention times (RT) and mass spectra (MS) of the compounds were analyzed by calculating the Kovats retention index (KI) and comparison with those in the W10N14 and NIST14 mass spectral databases. Animal experimental design Animals In this study, 35C57BL/6 male mice (25-30 g and 8 weeks old) [46] were obtained from institute for experimental animal research of Mazandaran university of medical sciences. They kept in cages in standard laboratory condition with free access to standard chew food and water at room temperature, under a 12h light/12h dark cycle. All experimental procedures were approved by the Ethics Committee of Mazandaran University of Medical Sciences, Sari, Iran (Ethical code: IR. MAZUMS.AEC.1402.048). Acute toxicity study Acute toxicity evaluation was conducted in accordance with OECD Guideline (Limit test). Based on this stepwise approach, initially a high starting dose of 1000 mg/kg from both fractions was administered to the mice (n=5 per dose) and the animal was monitored for 24 h. Since the initial dose led to more than three animals, lower dose levels were subsequently selected for both fractions. Based on the observation mortality pattern, the highest non-lethal doses were considered as LD50. Dosage lower than the one-tenth (1/10) and one-twentieth (1/20) of the LD50 were selected as the therapeutic doses to ensure a significant safety margin and avoid non-specific toxic effects during chronic administration. Study design and induction of MS CPZ mixed with animal normal feed at a concentration of 0.4% (w/w) and formulated into pelleted form by Royan Feed (Royan Biotechnology Institute, Isfahan, Iran). To confirm the induction of MS, mice were randomly selected at weeks 4, 6, and 8. Luxol fast blue (LFB) staining was performed to assess the myelin integrity in the corpus callosum region. After 8 weeks of administration [47], following brain tissue extraction, tissue sections were prepared from the middle one-third region including the corpus callosum area and hippocampus. After histopathological examination using hematoxylin and eosin (H&E) and LFB staining and confirmation of disease induction, the CPZ-containing diet was discontinued at the end of week 8 [37]. The mice were assigned to 7 groups (n=5 per group) included: 1) Normal group receiving standard diet, 2) CPZ group receiving standard diet supplemented with cuprizone, 3) Positive control receiving CPZ plus DMF at 100 mg/kg orally, 4) and 5) Treatment groups receiving CPZ plus GF at 1 and 10 mg/kg orally (CPZ + OFS 1and 10 mg/kg), 6) and 7) Treatment groups receiving CPZ plus VF at 1 and 10 mg/kg dissolved in ethanol(CPZ + SCFS 1and 10 mg/kg), respectively [48,49]. All of the treatment groups received 0.1 ml of insulin syringe BD. DMF was freshly prepared in 0.5% DMSO [50] and 0.5% ethanol with shaking by vortex and converted into a dispersed preparation [51]. Behavioral tests Rotarod test To evaluate motor coordination and balance in mice, the rotarod test was employed using a rotating metal rod measuring 3 cm in diameter and 14 cm in height, operating at a constant speed of 17 revolutions per minute (rpm). The latency period until the mice fell from the apparatus was recorded with a maximum duration of 300 s [22]. Open field test The open field test is a behavioral assay used to evaluate animal movements, and its results indicate motor impairments of animals. Mice were individually placed in a 60 × 60 with 30 cm high open field arena and their locomotor activity was recorded for 3 min. The movement of each animal were captured by an overhead video camera, and immobility time for each mouse was calculated and analyzed within a 180 s interval on days 14 and 21 [52]. Beam walk test The beam-walking apparatus consisted of a round wooden bar, 100 cm in length and 11 mm in diameter, elevated 50 cm above the floor. The beam's surface was coarse to provide adequate grip. A black box was positioned at one end of the beam to serve as a goal box and traverse the beam. A light source and an auditory stimulus were positioned at the starting point of the beam to encourage the mice to initiate traversal. The time taken to reach the target was calculated and analyzed [53]. Histopathological studies To examine myelin damage in the area of corpus callosum (CC), staining with LFB was employed; to examine inflammation and degenerated cells, H&E and Nissl staining were used to examine the neuronal status in the hippocampal region. For this purpose, one mouse per group was randomly selected on day 7, and two mice per group on days 14 and 21. The mice were anaesthetized with ketamine (100 mg/kg i. p.) and xylazine (10 mg/kg i. p) [46]. The brains of the mice were immediately extracted and immersed in buffered formalin (10%) for 24 h. Subsequently, the samples were embedded in paraffin, and coronal sections with a thickness of 5 μm were prepared using a microtome. Regarding the histological procedures, tissue sectioning was performed by an investigator who was blinded to the experimental groups to ensure unbiased sample preparation. Sections were then subjected to standardized staining protocols utilizing H&E, LFB staining as well as Cresyl Violet (Nissl) staining. Accordingly, slides were examined by using a Euromex KHW10×/20L light microscope (Netherlands) equipped with a KECAM microscope camera (China). For the quantitative analysis of myelinated fibers of the CC area, images were processed using ImageJ software version 10. The integrated intensity (IntDen), representing the product of the stained area and the mean signal intensity, was calculated to assess the total myelin load across different experimental groups. Raw data did not follow normal distribution pattern; therefore, we transformed data with logarithmic function. The normality of the data was assessed by the Shapiro-Wilk test. Afterward, the transformed data was analyzed with two-way ANOVA followed by Tukey's test [22]. Gene expression analysis A brain slice containing the corpus callosum region was subsequently immersed in RNA shield solution following its extraction, and was thereafter preserved at a temperature of −80°C. Total RNA was extracted employing the high pure RNA Isolation Kit in accordance with the manufacturer's instructions. The concentration and purity of the RNA were assessed spectrophotometrically through nucleotide absorption measurements at 260 nm and the 260/280 nm ratio (nucleotide/protein), respectively. RNA extraction from the tissues was executed utilizing the column RNA extraction kit (Pars Tous, Iran). The extracted RNA samples were utilized for the synthesis of cDNA using a specific cDNA synthesized kit (Zist virayesh, Iran) Its quality was evaluated using an electrophoresis apparatus [54]. Real time-polymerase chain reaction (RT-qPCR) analysis The primers for the target genes (Nrf2, NF-κB, Olig2, β-actin) were designed and procured from Metabiom company, Iran. The sequences of these primers are presented in the accompanying (Table 1). The β-actin gene was employed as a reference standard. In this investigation, subsequent to attaining the appropriate binding temperature for the desired primers, quantitative assessment of target gene expression was conducted utilizing RealQ Plus 2x Master Mix Green (Pars Tous, Iran) in conjunction with the Rotor Gene 6000 system. In this study, alterations in gene expression were appraised in relation to the expression level of the β-actin gene. The quantification of gene expression was achieved by calculating E−ΔΔCT [[54], [55], [56]].Table 1Primer sequences and thermal conditions for amplifying target genes by RT-qPCR.Table 1GenesPrimerThermal conditionNrf2CACATCCAGACAGACACCAGTGGGGAATGTCTCTGCCAAAAGCTG95 °C, 5 min35 cycles (95 °C, 20 s; 63 °C, 15 s)Melt (70-95 5 s/step)Olig2ATGCACGACCTCAACATCGCCAACCAGTCGCTTCATCTCCTCCA95 °C, 5 min35 cycles (95 °C, 20 s; 63 °C, 15 s)Melt (70-95 5 s/step)NF-κBGCTGCCAAAGAAGGACACGACAGGCAGGCTATTGCTCATCACAG95 °C, 5 min35 cycles (95 °C, 20 s; 64 °C, 15 s)Melt (70-95 5 s/step)β-actinCATTGCTGACAGGATGCAGAAGGTGCTGGAAGGTGGACAGTGAGG95 °C, 5 min35 cycles (95 °C, 20 s; 67 °C, 15 s)Melt (70-95 5 s/step) Table 1Primer sequences and thermal conditions for amplifying target genes by RT-qPCR.Table 1GenesPrimerThermal conditionNrf2CACATCCAGACAGACACCAGTGGGGAATGTCTCTGCCAAAAGCTG95 °C, 5 min35 cycles (95 °C, 20 s; 63 °C, 15 s)Melt (70-95 5 s/step)Olig2ATGCACGACCTCAACATCGCCAACCAGTCGCTTCATCTCCTCCA95 °C, 5 min35 cycles (95 °C, 20 s; 63 °C, 15 s)Melt (70-95 5 s/step)NF-κBGCTGCCAAAGAAGGACACGACAGGCAGGCTATTGCTCATCACAG95 °C, 5 min35 cycles (95 °C, 20 s; 64 °C, 15 s)Melt (70-95 5 s/step)β-actinCATTGCTGACAGGATGCAGAAGGTGCTGGAAGGTGGACAGTGAGG95 °C, 5 min35 cycles (95 °C, 20 s; 67 °C, 15 s)Melt (70-95 5 s/step) Primer sequences and thermal conditions for amplifying target genes by RT-qPCR. Statistical analysis Statistical analysis was performed using GraphPad Prism version 10. p value was considered statistically significant at the p < 0.05 threshold. All data were expressed as mean ± standard deviation (M ± SD). Statistical comparisons between groups were conducted using two-way (time × treatment) analysis of variance (ANOVA), followed by Tukey's post hoc test. Results Identification of the major glucosinolate The crude glucosinolates were extracted using 70% (V/V) boiling methanol from LSS and subsequently purified with a DEAE-Sephadex A-25. The collected fraction was initially monitored by TLC. Under UV radiation at 254 nm, a single distinct spot was observed, while no spots were detected at 365 nm. To further confirm the purity and homogeneity of the isolated compound, the TLC plates were visualized using iodine vapor and vanillin-sulfuric acid reagent. The appearance of a single spot with both reagents was detected that confirmed the purity of the fraction. The resulting glucosinolate fraction was then injected into the HPLC system for analysis. The analysis of GF revealed a distinct, sharp, and symmetrical peak at a retention time of 21 min (Fig. 1) with a relative area of 87.41% at 229 nm. Other observed peaks were minor, with the majority accounting for less than 1% of the total area, indicating the presence of a major compound, which was further characterized by NMR and mass spectrometry. (Fig. 2).Fig. 1Representative HPLC-UV chromatogram of the desulfo-glucosinolate fraction of L. sativum seeds recorded at 229 nm. The gradient elution system of water (A) and acetonitrile (B). The major peak eluting at Rt=21.0 min represents 87.41% of the total peak area.Fig. 2The chemical structure of the purified desulfo-glucotropaeolin. Representative HPLC-UV chromatogram of the desulfo-glucosinolate fraction of L. sativum seeds recorded at 229 nm. The gradient elution system of water (A) and acetonitrile (B). The major peak eluting at Rt=21.0 min represents 87.41% of the total peak area. The chemical structure of the purified desulfo-glucotropaeolin. The purified compound was characterized using 1H-NMR (D2O, 300 MHZ): 3.1-3.3 (4H, m, H-2′,3′,4′,5′), 3.52 (1H, dd, J5′,6′a = 4.9, J6′a, 6′b = 12.6, H-6′a), 3.58 (1H, dd, J5′,6′b =2.7, J6′a,6′b =12.6, H-6′b), 3.94 (2H, s, H-2), 4.6 (1H, dd, J1’, 2′ =6.9, J1’, 3′ =2.7, H-1′), 7.24-7.35(5H, m, Ar–H).13C-NMR: 37.91 (C-2), 60.3 (C-6′), 68.84 (C-4′), 71.96 (C-2′),76.99 (C-3′), 79.72 (C-5′), 81.02 (C-1′), 127.310 (C-6), 128.01 (C-5,7), 129.07 (C-4,8), 135.98 (C-3), 154.59 (C-1) [43,57]. EI-MS spectrum: The main mass fragments (m/z) including: 149 (C7H7NCS+), 91 (C6H5CH2+), 77 (C6H5+). GC-MS analysis of the volatile fraction The GC-MS analysis revealed the presence of glucotropaeolin degradation products which representing 58.65% of the total volatiles. The most abundant compound was identified as benzyl nitrile (40.7%) and benzyl isothiocyanate (BITC) (17.95%). Acute toxicity To determine the appropriate dose for in vivo studies, it is essential to assess the safety profile of the fractions. Ultimately, the LD50 values were determined to be 200 mg/kg for the GF (oral gavage) and 400 mg/kg for VF (SC). Effect of glucosinolate & volatile fraction on behavioral test Rotarod test Two-way ANOVA showed a significant effect of time as well as treatment groups. Furthermore, there was a notable interaction between time and treatment. Rotarod performance was significantly impaired in the CPZ group throughout the study (Fig. 3A, P < 0.001). No significant differences between treatment and CPZ groups were found on day 7. By day 14, only the CPZ + SCFS 1 mg/kg group did not show a statistically significant difference versus CPZ group and remaining groups showed significant differences compared to CPZ group (P < 0.001 and P < 0.01). On day 21, significant changes relative to CPZ were limited only CPZ + OFS 1 mg/kg and CPZ + OFS 10 mg/kg groups compared to CPZ (P < 0.001). Comparison between different days showed no significant difference within the CPZ group. A significant treatment effect was observed in nearly all treatment groups on both days 14 and 21 compared to day 7 (P < 0.001 and P < 0.01).Fig. 3The mice in all groups except the normal group were subjected to cuprizone-induced MS for 8 weeks, followed by treatment for 21 days, (A) Rotarod test, shows latency to fall, (B) Beam Walk test shows the time taken to reach the target. #P < 0.05, ##P< 0.01 and ###P < 0.001 vs the normal group and ∗P< 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs the CPZ group, @ P< 0.05,P < 0.001, && P< 0.01, ∧∧ P< 0.01, %%% P < 0.001, $$$ P < 0.001 indicates a significant difference of per group across different days, using two-way ANOVA followed by Tukey. The mice in all groups except the normal group were subjected to cuprizone-induced MS for 8 weeks, followed by treatment for 21 days, (A) Rotarod test, shows latency to fall, (B) Beam Walk test shows the time taken to reach the target. #P < 0.05, ##P< 0.01 and ###P < 0.001 vs the normal group and ∗P< 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs the CPZ group, @ P< 0.05,P < 0.001, && P< 0.01, ∧∧ P< 0.01, %%% P < 0.001, $$$ P < 0.001 indicates a significant difference of per group across different days, using two-way ANOVA followed by Tukey. Beam walk test As shown in Fig. 3B, the results indicated that time had a significant impact on the improvement of test outcomes. There was a significant difference in the Beam-walk test between the CPZ and the normal groups throughout the entire study period. Only one group showed a significant difference compared to the CPZ group on day 7. (P<0.01). There was a notable interaction between time and treatment groups with a more pronounced effect observed on day 14. All studied groups exhibited significant differences compared to the CPZ group on day 14 (P<0.001). This difference persisted on day 21 in only two groups, but with lower significance (P<0.05 and P<0.01). On day 14, the results indicated that significant differences were also present in the CPZ + SCFS 1 mg/kg and CPZ + SCFS 10 mg/kg groups (P<0.001 and P<0.01). Furthermore, on day 21, a significant difference compared to the day 7 was observed only in these two groups (P<0.05 and P<0.01). Open field test Two-way ANOVA showed a significant effect of time as well as treatment groups (Fig. 4). CPZ induced a significant effect on day 14. A significant change occurred within this group between days14 and 21 (P<0.001). Treatment groups CPZ + DMF, CPZ + OFS 1 mg/kg, CPZ + OFS 10 mg/kg and CPZ + SCFS 10 mg/kg showed significant improvement versus CPZ on day 14 (P < 0.001 and P < 0.01). In contrast, by day 21, no significant changes observed in any of the treatment groups compared to the CPZ. Inter group comparison also revealed that only on day 21, CPZ + SCFS (1 mg/kg) showed a significant compared to day 14 (P<0.05).Fig. 4The mice in all groups except the normal group were subjected to cuprizone-induced MS for 8 weeks, followed by treatment for 21 days, open field test shows immobility time of mice movement, #P < 0.05, ##P< 0.01 and ###P < 0.001 vs the CPZ group and ∗P< 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs the normal group, ∧P< 0.05, & P< 0.05, +++ P < 0.001 indicates a significant difference of per group across different days, using two-way ANOVA followed by Tukey. The mice in all groups except the normal group were subjected to cuprizone-induced MS for 8 weeks, followed by treatment for 21 days, open field test shows immobility time of mice movement, #P < 0.05, ##P< 0.01 and ###P < 0.001 vs the CPZ group and ∗P< 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs the normal group, ∧P< 0.05, & P< 0.05, +++ P < 0.001 indicates a significant difference of per group across different days, using two-way ANOVA followed by Tukey. Histopathological findings Effect of LSS fractions on cuprizone-induced alterations in brain myelination status H&E staining of the hippocampus region on day 21, revealed that normal group exhibited a significantly higher number of intact neurons compared to the other groups. Additionally, an increased presence of shrunken, pyknotic degenerated neurons was observed in CPZ, which was present in smaller numbers in treatment groups and observed at the lowest number in the CPZ + OFS 10 mg/kg group (Fig. 5). In Nissl staining, the Nissl bodies present in the cytoplasmic space of neurons are highlighted to evaluate cell death and assess neurons density. On the day 21 in normal group, intact neurons are shown as large cells with a distinct purple nucleus at the center. In contrast, the CPZ group exhibited reduced neuronal density and an increased number of astrocytes, indicating glial cell in response to demyelination and inflammation (Fig. 6). As shown in (Fig. 7A) of LFB staining, the myelinated neuronal fibers are visualized in blue, therefore, as demyelination progresses, the thickness and staining intensity in the CC region of the brain's white matter decrease. Both the regional thickness and staining intensity were reduced in CPZ group on day 21. The quantitative analysis revealed no statistically significant effect of time across the groups. However, significant differences between the normal and CPZ groups persisted throughout the study period (Fig. 7B). There was a significant difference among groups (effect size: 61.1% of the total variation). In the treatment groups, both the CPZ + DMF and CPZ + SCFS 10 mg/kg groups showed significant differences from the CPZ throughout all treatment days. In the CPZ + OFS 1 mg/kg and CPZ + SCFS 1 mg/kg groups, a significant difference was observed only on day 21, while in the CPZ + OFS 10 mg/kg, it was observed on days 14 and 21.Fig. 5The mice in all groups except the normal group were subjected to cuprizone-induced MS for 8 weeks, followed by treatment for 21 days with various groups including: 1: Normal, 2: CPZ, 3: CPZ + DMF, 4: CPZ + OFS 1 mg/kg, 5: CPZ + OFS 10 mg/kg, 6: CPZ + SCFS 1 mg/kg, 7: CPZ + SCFS 10 mg/kg, H&E staining of the hippocampus (× 200 Magnification, Scale bar=150 μm, n= 5/group), intact neurons (green arrows), shrunken degenerated neurons (red arrows) myelinated fiber (blue arrow).Fig. 6The mice in all groups except the normal group were subjected to cuprizone-induced MS for 8 weeks, followed by treatment for 21 days within various groups including: 1: Normal, 2: CPZ, 3: CPZ + DMF, 4: CPZ + OFS 1 mg/kg, 5: CPZ + OFS 10 mg/kg, 6: CPZ + SCFS 1 mg/kg, 7: CPZ + SCFS 10 mg/kg, Nissl staining of the hippocampus (× 400 Magnification, Scale bar=100 μm, n= 5/group), intact neurons (green arrows), shrunken degenerated neurons (red arrows) astrocytes (blue arrow).Fig. 7The mice in all groups except the normal group were subjected to cuprizone-induced MS for 8 weeks, followed by treatment for 21 days within various groups including: 1: Normal, 2: CPZ, 3: CPZ + DMF, 4: CPZ + OFS 1 mg/kg, 5: CPZ + OFS 10 mg/kg, 6: CPZ + SCFS 1 mg/kg, 7: CPZ + SCFS 10 mg/kg. A: LFB staining of the corpus callosum (× 200 Magnification, Scale bar=150 μm, n= 5/group), myelinated fiber (blue arrow), intact neurons (green arrows) B: Quantitative analysis of the CC by LFB staining. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.01, vs. NC group, #p < 0.05 and ##p < 0.01, ###p < 0.001, ####p < 0.0001 vs. CPZ group, using two-way ANOVA followed by Tukey. The mice in all groups except the normal group were subjected to cuprizone-induced MS for 8 weeks, followed by treatment for 21 days with various groups including: 1: Normal, 2: CPZ, 3: CPZ + DMF, 4: CPZ + OFS 1 mg/kg, 5: CPZ + OFS 10 mg/kg, 6: CPZ + SCFS 1 mg/kg, 7: CPZ + SCFS 10 mg/kg, H&E staining of the hippocampus (× 200 Magnification, Scale bar=150 μm, n= 5/group), intact neurons (green arrows), shrunken degenerated neurons (red arrows) myelinated fiber (blue arrow). The mice in all groups except the normal group were subjected to cuprizone-induced MS for 8 weeks, followed by treatment for 21 days within various groups including: 1: Normal, 2: CPZ, 3: CPZ + DMF, 4: CPZ + OFS 1 mg/kg, 5: CPZ + OFS 10 mg/kg, 6: CPZ + SCFS 1 mg/kg, 7: CPZ + SCFS 10 mg/kg, Nissl staining of the hippocampus (× 400 Magnification, Scale bar=100 μm, n= 5/group), intact neurons (green arrows), shrunken degenerated neurons (red arrows) astrocytes (blue arrow). The mice in all groups except the normal group were subjected to cuprizone-induced MS for 8 weeks, followed by treatment for 21 days within various groups including: 1: Normal, 2: CPZ, 3: CPZ + DMF, 4: CPZ + OFS 1 mg/kg, 5: CPZ + OFS 10 mg/kg, 6: CPZ + SCFS 1 mg/kg, 7: CPZ + SCFS 10 mg/kg. A: LFB staining of the corpus callosum (× 200 Magnification, Scale bar=150 μm, n= 5/group), myelinated fiber (blue arrow), intact neurons (green arrows) B: Quantitative analysis of the CC by LFB staining. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.01, vs. NC group, #p < 0.05 and ##p < 0.01, ###p < 0.001, ####p < 0.0001 vs. CPZ group, using two-way ANOVA followed by Tukey. Gene expression studies The expression of NF-κB, Nrf2 and Olig2 genes were evaluated in this study. Results demonstrated that no significant effect of time on the expression of genes Nrf2 and NF-κB was observed across the groups. The expression level of Nrf2 was significantly suppressed following CPZ administration (P<0.001) However, no significant difference was observed between the treatment groups and the CPZ group (Fig. 8A). On the other hand, the expression of the NF-κB the gene was significantly increased in the CPZ group compared to the normal group(P<0.001), whereas no significant difference was observed among the treatment groups and CPZ group. (Fig. 8B). The expression level of Olig2 as a marker for the assessment of oligodendrocytes, was significantly increased following CPZ administration. The results showed that the passage of time had a significant effect on the gene expression in the CPZ + OFS 10 mg/kg, CPZ + SCFS 1 mg/kg and CPZ+ 10 mg/kg groups. A significant decrease was also observed between the CPZ + DMF, CPZ + OFS 10 mg/kg, CPZ + SCFS 1 mg/kg and CPZ + SCFS 10 mg/kg groups in comparison CPZ group(P<0.001) (Fig. 8C).Fig. 8The mice in all groups except the normal group were subjected to cuprizone-induced MS for 8 weeks, followed by treatment for 21 days within various groups. The gene expression levels of Nrf2 (A), NF-κB (B), Olig2 (C), analyzed by qRT-PCR in various study groups. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 significant vs. the normal group; #P < 0.05, ##P < 0.01, ###P < 0.001, significant vs. the CPZ group (n = 5), + P< 0.05, && P< 0.01, &&& P < 0.001, ∧∧∧ P < 0.001,P < 0.001 indicates a significant difference of per group across different days, Densified value (D) of genes standardized to the respective β-actin. The mice in all groups except the normal group were subjected to cuprizone-induced MS for 8 weeks, followed by treatment for 21 days within various groups. The gene expression levels of Nrf2 (A), NF-κB (B), Olig2 (C), analyzed by qRT-PCR in various study groups. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 significant vs. the normal group; #P < 0.05, ##P < 0.01, ###P < 0.001, significant vs. the CPZ group (n = 5), + P< 0.05, && P< 0.01, &&& P < 0.001, ∧∧∧ P < 0.001,P < 0.001 indicates a significant difference of per group across different days, Densified value (D) of genes standardized to the respective β-actin. Discussion This study demonstrated that of GF and VF of LSS, can significantly enhance remyelination and exert neuroprotective effects in the cuprizone-induced C57BL/6 mice model of MS. The results indicated an enhancement in staining intensity in the LFB staining, accompanied by improvements in behavioral function tests. Moreover, significant changes in Olig2 expression were observed in the treatment groups, demonstrating the neuroprotective potential of the fractions. Given the lack of definitive MS treatments without side effects, investigating therapies with fewer adverse effects and lower costs is imperative [58]. This research has, for the first time, elucidated the impact of LSS fractions on CPZ-induced MS compared to the conventional medication; DMF. Studies suggest that MS is a complex disease characterized by interconnected immune, inflammatory, and oxidative processes [59]. In line with a recent meta-analysis highlighting the efficacy of dietary interventions in MS, our findings demonstrate the neuroprotective potential of Garden cress seeds as a functional food in the management of this disease [60]. CPZ administration in the mouse model of MS, allows researchers to examine the mechanisms associated with demyelination and the role of the inflammatory response in neuronal damage [61]. Animals in this model typically do not show significant motor deficits, such as paralysis, making it comparable to the early motor symptoms observed in humans with MS [22,62]. In this study, DMF served as the standard agent and positive control group for the treatment of MS symptoms, reducing inflammation and demyelination. This study demonstrated that administration of GF and VF fractions from LSS improved motor performance in mice, as evidenced by enhanced outcomes in rotarod and beam walk behavioral tests, with peak performance achieved on day 14. The open field test revealed a significant time-dependent decrease in immobility time in the CPZ group. Additionally, comparison between the treatment groups and the CPZ group indicated a significant improvement in performance, particularly on day 14. The peak efficacy observed at day 14 suggests that the treatment accelerates remyelination during the acute phase of injury. By day 21, the reduced difference between groups is attributed to the onset of spontaneous repair in the control group. Therefore, the intervention provides a crucial early neuroprotective advantage by accelerating the recovery process. This results has also been highlighted in previous studies [63]. Histopathological analysis with H&E staining revealed increased degenerated cells in the CPZ group compared with the normal group, with no statistically significant difference between the treatment and CPZ groups. Nissl staining was employed to assess neurodegeneration. Outcomes demonstrated increased numbers of degenerated cells and astrocyte proliferation in the CPZ group. A lower number of these cells was observed in the all-treatment groups, with the lowest count recorded in the CPZ + OFS 10 mg/kg group. The evaluation of myelination by LFB staining revealed a significant decrease in staining intensity in the CPZ group. Comparison between the treatment groups and the CPZ group revealed enhanced myelination with more pronounced significant differences in the CPZ + OFS 10 mg/kg and CPZ + SCFS 10 mg/kg groups. The gene expression results demonstrated that the treatment groups did not induce significant changes in the expression of Nrf2 and NF-κB. The observed results likely reflect the involvement of divergent molecular pathways acting at different phases of the disease. According to studies, gene expression varies at different stages of CPZ administration in this model of MS [64]. In a study by Zhang et al. on KM female mice with CPZ induced multiple sclerosis, the compound Myricetin was shown to improve LFB staining and rotarod test performance after 5 weeks of administration. Analysis of Nrf2 protein expression indicated a reduction in nuclear localization, whereas cytoplasmic levels remained unchanged, suggesting that neuroprotective effects may be mediated via different pathways [65]. Thus, the absence of significant alterations in Nrf2 and NF-κB expression in the current study can be explained. Olig2 is recognized as a critical transcription factor in oligodendrocyte developments and myelin synthesis [66]. In the groups receiving CPZ, an increase in Olig2 expression was observed, whereas a significant reduction was noted in the treatment groups compared to this baseline. This gene is critical for the differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes; therefore, its elevation in the CPZ group is likely a natural response of OPCs to the demyelination process. Conversely, the decrease in Olig2 expression in the treatment groups may stem from the drug's protective effect on preserving mature oligodendrocyte survival. This preservation could lead to a reduced need for OPC differentiation into mature cells, consequently lowering Olig2 gene expression. Furthermore, the maintenance of mature oligodendrocytes may facilitate myelin repair, as evidenced by the tissue analysis using LFB staining. On the other hand, alternative pathways, such as the activation of Myelin Basic Protein (MBP) and Proteolipid Protein (PLP) expression, may contribute to myelination and operate independently of Olig2 gene expression [67]. Remyelination can occur through growth factors independently of inflammation. On the other hand, Olig2 expression occurs predominantly during the remyelination phase, more so than NF-κB and Nrf2 [68,69]. Zhang et al., demonstrated that 12 weeks of Quetiapine treatment in C57BL/6 mice enhanced the number of mature oligodendrocytes. This intervention was associated with a reduction in Olig2 expression during the maturation process of oligodendrocyte precursor cells [70]. Therefore, it can be inferred that remyelination in the outcomes of this study may occur independently of pathways associated with inflammation resolution and Olig2 gene expression. The identification of the GF fraction indicated the presence of the glucotropaeolin. The study by Williams et al., also reported glucotropaeolin as the predominant glucosinolate present in LSS [8]. The results of this study indicated neuroprotective effects in the groups receiving oral GF at both doses of 1 and 10 mg/kg in mice. Oral administration of this class of compounds in mammals undergoes hydrolysis into degradation products, primarily isothiocyanates. In a study conducted on male Wistar rats to investigate the metabolism of orally administered glucosinolates, it was determined that the major degraded compounds of glucotropaeolin include isothiocyanates, thiocyanate and cyanide ions was found in the blood serum of the rats [71]. Glucosinolates do not directly and freely cross the BBB due to their polar and large molecular structure. However, their metabolites, such as isothiocyanates, can exert their anti-inflammatory effects by crossing the BBB. Studies have demonstrated that glucosinolates like glucoraphanin maintain the integrity of tight junctions and prevent the infiltration of inflammatory factors, including cytokines and inflammatory cells like lymphocytes, thereby inhibiting the spread of inflammation [33,72]. Unlike the structure of glucotropaoelin, BITC, its hydrolysis product, has a small, non-polar structure that can pass through BBB [73]. In studies investigating the BBB permeability of this class of compounds, it was demonstrated that isothiocyanates, such as sulforaphane, are detectable in brain tissue due to their low molecular weight and lipophilicity. Consequently, BITC, with its lower molecular weight (149 Da) and higher lipophilicity than Sulforaphane, may have a greater ability to cross the BBB [74]. Accordingly, this superior lipophilicity promotes better interaction with intracellular molecular targets, which in turn enhances its potency in activating antioxidant responses and promoting apoptotic mechanisms [75]. In addition to the glucosinolate fraction of LSS, its corresponding volatile fraction was also investigated. The GC-MS profile of VF in this study, revealed that the compounds with the highest abundance percentages were benzyl nitrile and benzyl isothiocyanate which is derived from the hydrolysis of glucotropaeolin. Given that no specific neuroprotective effect has been attributed to benzyl nitrile in the literature, the observed efficacy of the VF is likely attributable to its BITC component. While isothiocyanates are the primary focus, the potential synergistic or minor contribution of nitrile derivatives remains an area for future specialized investigation. Previous studies have also highlighted the presence of these two compounds as the predominant constituents in the fraction [76,77]. This study results, demonstrated that although neuroprotective efficacy was observed in both fractions, the OFS fraction, which contains the compound glucotropeolin, particularly at a dose of 10 mg, exhibited superior effects. The therapeutic efficacy of glucotropaeolin is further elucidated by the novel mechanisms recently identified by Lucarini et al. Their study demonstrated that glucotropaeolin and BITC, a derivative of glucotropaeolin hydrolysis, act as a hydrogen sulfide donor, providing potent cytoprotection and antioxidant effects independently of the Nrf2/ARE pathways. These compounds also interfere with the signaling cascade of the neurogenic inflammation thereby preventing the infiltration of mast cells and limiting the recruitment of other pro-inflammatory mediators to the tissue. Additionally, these compounds significantly reduce neuroinflammation markers and modulates substance P levels [78]. This can be attributed to the fact that a major portion of glucotropaeolin present in this fraction is converted to the compound BITC, which is also found in the volatile fraction, thereby suggesting that BITC plays a crucial role in the observed neuroprotective effects. Studies have shown that isothiocyanates can activate the Nrf2 pathway and can diminish neuroinflammation by inhibiting the translocation of NF-κB as well as the generation of oxidative species and the death of neurons through apoptosis [34,73]. Experiments have established BITC efficacy to be owing to its antioxidant and anti-inflammatory activities, alongside its role in regulating the cell cycle, mitochondrial function, and apoptotic pathways, which are implicated in cell and tissue relief of chronic inflammation [79]. The results of this study did not show a significant change in the expression of Nrf2 and NF-κB genes in the treatment groups. Studies have demonstrated that anti-inflammatory mechanisms of ITCs like sulforaphane can operate independently of gene activation pathways such as Nrf2. Additionally, the expression of Nrf2 itself is influenced by factors including the dosage administered [80]. Multiple studies have investigated the efficacy of this class of compounds in animal models of MS. Galuppo et al., investigated the anti-inflammatory effects of the bioactive glucomoringin in EAE-induced C57Bl/6 male mice. This study demonstrated that this compound can reduce TNF-α expression in spinal cord cells [81]. In a similar study, the anti-inflammatory effects of a myrosinase-activated glucoraphanin were investigated in an experimental mouse model of MS. The results demonstrated that treatment with this bioactive compound significantly reduced the expression of inflammatory proteins such as IL-1β, which was achieved through the inhibition of inflammatory and apoptotic processes [32]. Therefore, based on the findings of present study and previous research, future studies should evaluate key proteins such as MBP and PLP, using Western blot and immunohistochemistry (IHC) to further elucidate the underlying mechanisms. Conclusion Our results demonstrated that both fractions of cress seeds exhibit neuroprotective effects and enhanced remyelination, compare to CPZ group. Findings indicate that glucotropaeolin and its hydrolysis products were able to induce remyelination by increasing the intensity of LFB staining and behavioral test. Given that no significant changes were observed in the expression of Nrf2 and Nf-κB and decrease in Olig2 expression was noted in the treatment groups, it appears that these compounds exert their neuroprotective effects through alternative pathways. Considering that this plant is an edible, accessible, and economically feasible herb, the observed neuroprotective effects suggest it could be regarded as a promising therapeutic candidate in future studies. Limitations The present study has some limitations that should be acknowledged. Although significant behavioral and histological improvements were observed, the molecular investigation into specific mechanistic pathways was not exhaustive. This suggests the involvement of other compensatory mechanisms that were not fully captured in the current study. Therefore, these proposed pathways should be considered as hypotheses for further exploration. Furthermore, while the sample size was constrained by logistical factors, the statistical power was sufficient to yield significant and reliable results. Given the short-term evaluation intervals inherent to the cuprizone model, the potential influence of memory traces was not evaluated in this study and should be considered when interpreting these behavioral outcomes. Finally, due to resource-related constraints, certain markers, such as specific inflammatory cytokines and key functional proteins were not evaluated, which could be addressed in subsequent investigations. Ethics approval All in vivo animal procedures in this study followed the ethical guidelines of working with laboratory animals conducted at institute for experimental animal research of Mazandaran University of medical sciences and were approved by the ethical committee with Ethical code (IR.MAZUMS.ACE.1402.048). Funding This work was supported by 10.13039/501100004160Mazandaran University of Medical Sciences, Sari, Iran (grant No.17145). CRediT authorship contribution statement Masoumeh Bathaee: Data curation, Investigation, Software, Visualization, Writing – original draft. Mohammad Seyedabadi: Formal analysis, Methodology, Writing – review & editing. Mohammad Shokati Sayyad: Formal analysis, Investigation. Somayeh Sheidaei: Formal analysis, Methodology. Somayeh Shahani: Conceptualization, Formal analysis, Methodology, Supervision, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.